- Home
- CNTX
as 06-20-2025 3:33pm EST
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 78.0M | IPO Year: | 2021 |
| Target Price: | $6.00 | AVG Volume (30 days): | 390.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.49 - $2.75 | Next Earning Date: | 08-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Context Therapeutics Inc. (CNTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lehr Martin A. | CNTX | Chief Executive Officer | Jun 9 '25 | Buy | $0.70 | 100,000 | $70,080.00 | 920,190 | |
| Minai-Azary Jennifer Lynn | CNTX | Chief Financial Officer | Jun 6 '25 | Buy | $0.64 | 40,010 | $25,486.37 | 80,010 | |
| Levit Alex C. | CNTX | Chief Legal Officer, Corp. Sec | Jun 6 '25 | Buy | $0.58 | 20,000 | $11,520.00 | 29,000 |
Latest Context Therapeutics Inc. News
CNTX Breaking Stock News: Dive into CNTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Co-Founder of Context Therapeutics Martin Lehr Buys 10% More Shares
GlobeNewswire
19 days ago
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
GlobeNewswire
23 days ago
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
GlobeNewswire
a month ago
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
GlobeNewswire
2 months ago
Context Therapeutics Announces Chief Medical Officer Transition
GlobeNewswire
2 months ago
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
MT Newswires
2 months ago
William Blair Initiates Context Therapeutics at Outperform
Compare CNTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTX Context Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.